Abstract
T cells have originally occupied central stage of the debate on the type of lymphocytes governing the pathogenesis of Sjögren’s syndrome (SS). However, B cells has since been substituted for T cells, and insights into their functions have revealed that they accomplish various tasks. Beyond the paradigm that T lymphocytes maintain strict control over B lymphocytes, these latter cells solicit their own help from the former, release a flurry of cytokines, and act as antigen- presenting cells. In SS, excessive of the B cell-activating factor (BAFF) may cause B-cell quantitative anomalies, such as inflation of mature B (Bm)2/Bm2’ cells in the circulation, or accumulation of transitional type 2, marginal zone (MZ) and memory B cells within the exocrine gland infiltrates. These excesses are also associated with B-cell qualitative anomalies, such as the internal synthesis of BAFF, and a default mechanism that promotes the autoantibody production in ectopic germinal centers or MZ equivalents. Thus, SS should rather be conceived as a quintessential model for B cellinduced autoimmunity. Such a view opens novel prospects for treatment, and indeed B cell-ablative therapy has already been shown to be beneficial to these patients.
Keywords: B lymphocyte, Sjogren's syndrome, B cell activating factor, ectopic germinal centers, T cells, pathogenesis, lymphocytes, cytokines, antigen-presenting cells, marginal zone, internal synthesis, MZ equivalents, B cell-ablative therapy, salyvary gland (SG), rheumatoid arthritis (RA).
Current Pharmaceutical Biotechnology
Title:B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome
Volume: 13 Issue: 10
Author(s): Pierre Youinou, Alain Saraux and Jacques-Olivier Pers
Affiliation:
Keywords: B lymphocyte, Sjogren's syndrome, B cell activating factor, ectopic germinal centers, T cells, pathogenesis, lymphocytes, cytokines, antigen-presenting cells, marginal zone, internal synthesis, MZ equivalents, B cell-ablative therapy, salyvary gland (SG), rheumatoid arthritis (RA).
Abstract: T cells have originally occupied central stage of the debate on the type of lymphocytes governing the pathogenesis of Sjögren’s syndrome (SS). However, B cells has since been substituted for T cells, and insights into their functions have revealed that they accomplish various tasks. Beyond the paradigm that T lymphocytes maintain strict control over B lymphocytes, these latter cells solicit their own help from the former, release a flurry of cytokines, and act as antigen- presenting cells. In SS, excessive of the B cell-activating factor (BAFF) may cause B-cell quantitative anomalies, such as inflation of mature B (Bm)2/Bm2’ cells in the circulation, or accumulation of transitional type 2, marginal zone (MZ) and memory B cells within the exocrine gland infiltrates. These excesses are also associated with B-cell qualitative anomalies, such as the internal synthesis of BAFF, and a default mechanism that promotes the autoantibody production in ectopic germinal centers or MZ equivalents. Thus, SS should rather be conceived as a quintessential model for B cellinduced autoimmunity. Such a view opens novel prospects for treatment, and indeed B cell-ablative therapy has already been shown to be beneficial to these patients.
Export Options
About this article
Cite this article as:
Youinou Pierre, Saraux Alain and Pers Jacques-Olivier, B-Lymphocytes Govern the Pathogenesis of Sjogren's Syndrome, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273100
DOI https://dx.doi.org/10.2174/138920112802273100 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
25th Anniversary Special Issue.
Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more
Applications and Challenges of Nano-Biotechnology
This thematic issue aims to introduce readers to the fascinating intersection of nanotechnology and biology. It will bring together fundamental principles, materials, tools, and recent breakthroughs to help learners, researchers, and innovators understand how nanoscale science is revolutionizing biological and medical applications. Contributing authors will submit papers related to foundational ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued) Interstitial Lung Disease in Sjogrens Syndrome
Current Rheumatology Reviews Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Influence of Hormones on Sjögren’s Syndrome
Current Pharmaceutical Design Otorhinolaryngological Manifestations in Sjogren Syndrome
Current Immunology Reviews (Discontinued) Co-Existence of Sarcoidosis and Sjögren’s Syndrome with Hypercalcemia and Renal Involvement: A Case Report and Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Status of Molecular Imaging in Inflammatory and Autoimmune Disorders
Current Pharmaceutical Design IL-27: Friend or Foe in the Autoimmune Diseases
Current Immunology Reviews (Discontinued) Mixed Connective Tissue Disease (MCTD) and Undifferentiated Connective Tissue Disease (UCTD)
Current Rheumatology Reviews Sjogrens Syndrome and Lymphoma Development
Current Immunology Reviews (Discontinued) From Molecular Mechanism to the Etiology of Sjogren Syndrome
Current Pharmaceutical Design TLR7/9 Antagonists as Therapeutics for Immune-Mediated Inflammatory Disorders
Inflammation & Allergy - Drug Targets (Discontinued) The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases
Current Pharmaceutical Design Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design New Organ-Specific Pharmacological Strategies Interfering With Signaling Pathways In Inflammatory Disorders/Autoimmune Disorders
Current Signal Transduction Therapy Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Treatment Strategies and Potential Therapeutic Targets in Primary Sjogrens Syndrome
Inflammation & Allergy - Drug Targets (Discontinued) Unique Phenotypes and Functions of Follicular Helper T Cells and Regulatory T Cells in Sjögren’s Syndrome
Current Rheumatology Reviews Cardiovascular Disease in Primary Sjögren’s Syndrome
Reviews on Recent Clinical Trials A Common Pathway for All Autoimmune Diseases? The Unholy Alliance of Environment, Cell Death and Nucleic Acids
Current Immunology Reviews (Discontinued)